Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
Status:
Terminated
Trial end date:
2016-05-18
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the effect of natalizumab compared to
fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to
persistent black holes (PBH) over 52 weeks. The secondary objectives of this study in this
study population are to assess the effect of natalizumab compared to fingolimod on: magnetic
resonance imaging (MRI) measures of central nervous system (CNS) tissue destruction as
measured by the number of new T1-Gd+ lesions; various other MRI measures of disease activity;
No Evidence of Disease Activity (NEDA); Relapse on treatment over 52 weeks; The change in
information processing speed as measured by the Symbol Digit Modalities Test (SDMT).